Khiron Life Sciences Corp.. Announces Formation of Wellness Business Unit and the Launch of Its First CBD Cosmeceutical Brand

Khiron Life Sciences Corp..

Announces Formation of Wellness Business Unit and the Launch of Its First CBD Cosmeceutical Brand

Khiron Life Sciences Corp. (“Khiron” or the”Company“) (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today the creation of Khiron Wellness, and the launching of Kuida®, its initial CBD-based skincare brand. With this achievement, reg Kuida &; becomes the first brand approved Colombia by INVIMA & acute;s health bureau, and available for sale in Colombia.

Khiron Life Sciences launches Kuida, first mass-market CBD consumer brand in Colombia (CNW Group/Khiron Life Sciences Corp.)

Khiron’s Wellness business unit is focused on nutraceutical and cosmeceutical products, offering consumers across Latin America the full advantages of cannabis.

Kuida® is the first brand in Colombia that brings the advantages of Cannabidiol (CBD) to a comprehensive portfolio of skin and body care products for women. Kuida® advances CBD and advanced cosmeceutical ingredients to make our proprietary CBDERM® technology, which is demonstrated to be three times more antioxidant than vitamin E, together with anti-aging attributes, speedy absorption and light textures to enhance the skin penetration of CBD.

The full Kuida® product portfolio can be found at www.Kuidaskincare.com

Alvaro Torres, Co-founder and Chief Executive Officer stated,”In keeping with our stated strategy, the Khiron Wellness business unit and launching of Kuida® leverages our global medical cannabis experience to enter a fast-growing group with instant revenue generation based on a disruptive, innovative and first-to-market product strategy. We will be launching Kuida® across the region, while developing consumer packaged goods. Furthermore, Khiron will continue to achieve its milestones related to the ongoing expansion of our cannabis cultivation, development of health products, and clinics rollout.”

According to Euromonitor, the skincare market in Colombia is over US $5.6 Billion in annual sales, with a growth rate of 6 percent in the past five years. What’s more, the Latin American skincare market is anticipated to reach US $110 Billion by 2020.

Andres Galofre, Co-founder and Chief Commercial Officer stated,”I want to congratulate our staff for their dedication in bringing Kuida®, the first INVIMA-approved, CBD-based skincare brand to the market. We know and promote the advantages of CBD-based cosmeceuticals and the capacity for Kuida® to have a positive impact on women’s lives, beauty, and well-being across Latin America”.

Kuida® will launch and will be a major sponsor at the XVII Feria de Belleza y Salud taking place in Bogota, Colombia from October 3-7, 2018. This event is the largest health and beauty conference in Colombia attracting more than 55,000 attendees to find trends and new products . Full event details can be found at www.feriabellezaysalud.com

Khiron launches Kuida® with one of Colombia&extreme;s leading influencers and recognized character, Ms. Catalina Aristizabal, as ambassador for the Kuida® manufacturer. A model, actress and wellness advocate, Ms. Aristizabal has starred in hit TV programs, in film, as a judge on the popular Colombia’s Next Top Model TV show, and hostess of Colombia´s top rated reality show during the last two years. “Whether on screen or at home with my family, I work hard to live a healthy life every single day. Kuida® is already a part of my daily skincare routine and I am proud to support the brand in helping other women feel beautiful”, remarks Mrs. Aristizabal.

Having a prominent social media presence, including nearly 1.5 million Instagram followers, and a well-known passion for healthy living, Mrs. Aristizabal will represent Kuida® at beauty and lifestyle events, and feature prominently in Kuida®´s marketing plan, complementing the more than 300 Kuida® brand influencers.

Khiron Life Sciences Corp.  (TSXv: KRHN, OTCQB: KHRNF, Frankfurt: A2JMZC) (“Khiron” or the”Company”) is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the nation for the cultivation, production, domestic distribution, and global export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron listed becoming the Colombian based medical cannabis company.

With a concentrated regional strategy and individual oriented approach, the Company combines global scientific experience, agricultural advantages, branded product market entry expertise and education to drive prescription and brand loyalty to handle priority medical conditions such as chronic pain, epilepsy, depression and anxiety at the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a Board. 

Further details on Khiron Life Sciences can be found at www.khiron.ca.

This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, which are not based on historical fact, including without limitation statements containing the words”believes”,”expects”,”plans”,”intends”,”will”,”should”,”anticipates”,”continue”,”estimate”,”forecasts” and other similar expressions. Readers are cautioned not to place undue reliance. Developments and actual results may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Though Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Filing Statement that is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information are made as of the date hereof and is qualified by this cautionary statement. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2018/28/c7503.html

Released at Fri, 28 Sep 2018 11:11:59 +0000

Posted in: News

Comments are closed.